BNP Paribas Financial Markets’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.5K Sell
4,251
-56,930
-93% -$53.8K ﹤0.01% 5496
2026
Q1
$56.2K Sell
61,181
-16,437
-21% -$19.9K ﹤0.01% 4632
2025
Q4
$99.4K Buy
77,618
+19,292
+33% +$25.9K ﹤0.01% 4382
2025
Q3
$75.8K Buy
58,326
+28,500
+96% +$37.3K ﹤0.01% 4418
2025
Q2
$35.8K Buy
29,826
+9,986
+50% +$11.1K ﹤0.01% 4375
2025
Q1
$21.4K Sell
19,840
-15,164
-43% -$21.3K ﹤0.01% 4520
2024
Q4
$61.3K Sell
35,004
-60,002
-63% -$112K ﹤0.01% 4343
2024
Q3
$183K Sell
95,006
-41,231
-30% -$80.7K ﹤0.01% 3282
2024
Q2
$241K Buy
136,237
+118,477
+667% +$290K ﹤0.01% 3035
2024
Q1
$48.1K Buy
17,760
+17,759
+1,775,900% +$42.9K ﹤0.01% 3574
2023
Q4
$2 Hold
1
﹤0.01% 3998
2023
Q3
$3 Hold
1
﹤0.01% 3904
2023
Q2
$2 Sell
1
-23
-96% -$45 ﹤0.01% 3909
2023
Q1
$47 Sell
24
-263
-92% -$520 ﹤0.01% 3797
2022
Q4
$336 Buy
287
+23
+9% +$28 ﹤0.01% 3890
2022
Q3
$290 Sell
264
-5,771
-96% -$8.72K ﹤0.01% 4578
2022
Q2
$9.66K Sell
6,035
-12,038
-67% -$29.8K ﹤0.01% 3753
2022
Q1
$64.9K Sell
18,073
-9,864
-35% -$34.1K ﹤0.01% 3491
2021
Q4
$110K Buy
27,937
+10,592
+61% +$49.6K ﹤0.01% 3567
2021
Q3
$114K Buy
17,345
+11,260
+185% +$74.1K ﹤0.01% 3222
2021
Q2
$37.5K Sell
6,085
-23,220
-79% -$124K ﹤0.01% 3370
2021
Q1
$132K Buy
29,305
+14,746
+101% +$81K ﹤0.01% 3226
2020
Q4
$87.4K Sell
14,559
-3,316
-19% -$21.8K ﹤0.01% 3276
2020
Q3
$133K Buy
17,875
+12,043
+206% +$83.1K ﹤0.01% 2965
2020
Q2
$23.4K Sell
5,832
-15,480
-73% -$53.9K ﹤0.01% 3330
2020
Q1
$54.1K Buy
21,312
+11,296
+113% +$37.1K ﹤0.01% 3501
2019
Q4
$34.9K Buy
10,016
+127
+1% +$447 ﹤0.01% 3828
2019
Q3
$45.8K Buy
9,889
+5,835
+144% +$46K ﹤0.01% 3526
2019
Q2
$49.9K Sell
4,054
-2,795
-41% -$35.6K ﹤0.01% 3418
2019
Q1
$91K Buy
6,849
+6,661
+3,543% +$70.2K ﹤0.01% 3177
2018
Q4
$1.62K Sell
188
-395
-68% -$3.08K ﹤0.01% 3836
2018
Q3
$4.37K Sell
583
-214
-27% -$1.52K ﹤0.01% 4113
2018
Q2
$4.75K Sell
797
-8,232
-91% -$46.9K ﹤0.01% 4118
2018
Q1
$52.7K Buy
9,029
+243
+3% +$1.6K ﹤0.01% 3533
2017
Q4
$51.8K Buy
8,786
+5,984
+214% +$32.8K ﹤0.01% 3649
2017
Q3
$14.1K Sell
2,802
-223
-7% -$937 ﹤0.01% 3765
2017
Q2
$12.2K Buy
3,025
+2,921
+2,809% +$13.8K ﹤0.01% 3891
2017
Q1
$592 Sell
104
-1,477
-93% -$9.36K ﹤0.01% 3819
2016
Q4
$11.5K Sell
1,581
-435
-22% -$2.73K ﹤0.01% 3389
2016
Q3
$16.1K Buy
2,016
+884
+78% +$8.12K ﹤0.01% 3010
2016
Q2
$10.2K Buy
1,132
+1,063
+1,541% +$9.99K ﹤0.01% 2906
2016
Q1
$557 Sell
69
-5,617
-99% -$40.5K ﹤0.01% 2548
2015
Q4
$61.5K Sell
5,686
-190
-3% -$1.87K ﹤0.01% 2658
2015
Q3
$47.7K Buy
5,876
+3,466
+144% +$54.6K ﹤0.01% 2904
2015
Q2
$58.3K Buy
2,410
+1,736
+258% +$54.8K ﹤0.01% 2401
2015
Q1
$28.4K Buy
+674
New +$26.6K ﹤0.01% 2198
2014
Q4
Sell
-1,793
Closed -$43.9K 2627
2014
Q3
$43.9K Buy
+1,793
New +$50.4K ﹤0.01% 2674
2014
Q2
Sell
-55
Closed -$2.07K 3890
2014
Q1
$2.07K Sell
55
-292
-84% -$12.8K ﹤0.01% 2648
2013
Q4
$13.3K Buy
+347
New +$10.2K ﹤0.01% 2468

Other funds holding LAB

BNP Paribas Financial Markets's LAB Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Standard BioTools (LAB) stake by 93% in Q2 2026, selling an estimated $53.8K and leaving 4,251 shares worth $3.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5496.

BNP Paribas Financial Markets first reported a position in LAB in Q4 2013 and has held it in 49 quarters since. The position peaked at $241K in Q2 2024. 128 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • BNP Paribas Financial Markets held 4,251 shares of Standard BioTools worth $3.5K as of Q2 2026.
  • BNP Paribas Financial Markets sold 56,930 Standard BioTools shares in Q2 2026, an estimated $53.8K.
  • Standard BioTools made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5496 holding.
  • BNP Paribas Financial Markets first reported a position in Standard BioTools in Q4 2013 and has held it in 49 quarters since.
  • BNP Paribas Financial Markets's Standard BioTools position peaked at $241K in Q2 2024.
  • 128 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.